SEARCH

SEARCH BY CITATION

References

  • Astermark, J. , Berntorp, E. , White, G.C. & Kroner, B.L. (2001) The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia, 7, 267272.
  • Astermark, J. , Altisent, C. , Batorova, A. , Diniz, M.J. , Gringeri, A. , Holme, P.A. , Karafoulidou, A. , Lopez-Fernandez, M.F. , Reipert, B.M. , Rocino, A. , Schiavoni, M. , von, D.M. , Windyga, J. & Fijnvandraat, K. (2010) Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report. Haemophilia, 16, 747766.
  • Bril, W.S. , MacLean, P.E. , Kaijen, P.H. , van den Brink, E.N. , Lardy, N.M. , Fijnvandraat, K. , Peters, M. & Voorberg, J. (2004) HLA class II genotype and factor VIII inhibitors in mild haemophilia A patients with an Arg593 to Cys mutation. Haemophilia, 10, 509514.
  • van den Brink, E.N. , Timmermans, S.M. , Turenhout, E.A. , Bank, C.M. , Fijnvandraat, K. , Voorberg, J. & Peters, M. (1999) Longitudinal analysis of factor VIII inhibitors in a previously untreated mild haemophilia A patient with an Arg593–>Cys substitution. Thrombosis and Haemostasis, 81, 723726.
  • Colvin, B.T. , Hay, C.R. , Hill, F.G. & Preston, F.E. (1995) The incidence of factor VIII inhibitors in the United Kingdom, 1990–93. Inhibitor Working Party. United Kingdom Haemophilia Centre Directors Organization. British Journal of Haematology, 89, 908910.
  • Coppola, A. , Di Minno, M.N. & Santagostino, E. (2010) Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. British Journal of Haematology, 150, 515528.
  • Eckhardt, C.L. , Menke, L.A. , Van Ommen, C.H. , Van Der Lee, J.H. , Geskus, R.B. , Kamphuisen, P.W. , Peters, M. & Fijnvandraat, K. (2009) Intensive peri-operative use of factor VIII and the Arg593 -> Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A. Journal of Thrombosis and Haemostasis, 7, 930937.
  • Fijnvandraat, K. , Turenhout, E.A. , van den Brink, E.N. , ten Cate, J.W. , van Mourik, J.A. , Peters, M. & Voorberg, J. (1997) The missense mutation Arg593 –> Cys is related to antibody formation in a patient with mild hemophilia A. Blood, 89, 43714377.
  • Gouw, S.C. & van den Berg, H.M. (2009) The multifactorial etiology of inhibitor development in hemophilia: genetics and environment. Seminars in thrombosis and Hemostasis, 35, 723734.
  • Hay, C.R. , Ludlam, C.A. , Colvin, B.T. , Hill, F.G. , Preston, F.E. , Wasseem, N. , Bagnall, R. , Peake, I.R. , Berntorp, E. , Mauser Bunschoten, E.P. , Fijnvandraat, K. , Kasper, C.K. , White, G. & Santagostino, E. (1998) Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation.[see comment]. Thrombosis and Haemostasis, 79, 762766.
  • Hay, C.R. , Palmer, B. , Chalmers, E. , Liesner, R. , Maclean, R. , Rangarajan, S. , Williams, M. & Collins, P.W. (2011) Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood, 117, 63676370.
  • Jacquemin, M. , Vantomme, V. , Buhot, C. , Lavend'homme, R. , Burny, W. , Demotte, N. , Chaux, P. , Peerlinck, K. , Vermylen, J. , Maillere, B. , van der, B.P. & Saint-Remy, J.M. (2003) CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A. Blood, 101, 13511358.
  • Kempton, C.L. , Soucie, J.M. , Miller, C.H. , Hooper, C. , Escobar, M.A. , Cohen, A.J. , Key, N.S. , Thompson, A.R. & Abshire, T.C. (2010) In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study. Journal of Thrombosis and Haemostasis, 8, 22242231.
  • Leebeek, F.W. , Kappers-Klunne, M.C. & Jie, K.S. (2004) Effective and safe use of recombinant factor VIIa (NovoSeven) in elderly mild haemophilia A patients with high-titre antibodies against factor VIII. Haemophilia, 10, 250253.
  • Mannucci, P.M. (2000) Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years. Haemophilia, 6(Suppl 1), 6067.
  • Matzinger, P. (2002) The danger model: a renewed sense of self. Science, 296, 301305.
  • Mauser- Bunschoten, E.P. , Fransen De Putte Van, D.E. & Schutgens, R.E. (2009) Co-morbidity in the ageing haemophilia patient: the down side of increased life expectancy. Haemophilia, 15, 853863.
  • Oldenburg, J. , El-Maarri, O. & Schwaab, R. (2002) Inhibitor development in correlation to factor VIII genotypes. [Review] [37 refs]. Haemophilia, 8(Suppl 2), 2329.
  • Peerlinck, K. & Jacquemin, M. (2010) Mild haemophilia: A disease with many faces and many unexpected pitfalls. Haemophilia, 16, 100106.
  • Plug, I. , van der Bom, J.G. , Peters, M. , Mauser-Bunschoten, E.P. , van de Goede-Bolder, A. , Heijnen, L. , Smit, C. , Zwart-van Rijkom, J.E. , Willemse, J. & Rosendaal, F.R. (2004) Thirty years of hemophilia treatment in the Netherlands, 1972-2001. Blood, 104, 34943500.
  • Sharathkumar, A. , Lillicrap, D. , Blanchette, V.S. , Kern, M. , Leggo, J. , Stain, A.M. , Brooker, L. & Carcao, M.D. (2003) Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. Journal of thrombosis and haemostasis, 1, 12281236.
  • Thompson, A.R. , Murphy, M.E. , Liu, M. , Saenko, E.L. , Healey, J.F. , Lollar, P. & Scandella, D. (1997) Loss of tolerance to exogenous and endogenous factor VIII in a mild hemophilia A patient with an Arg593 to Cys mutation. Blood, 90, 19021910.
  • Verbruggen, B. , Novakova, I. , Wessels, H. , Boezeman, J. , van den Berg, M. & Mauser-Bunschoten, E. (1995) The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thrombosis and Haemostasis, 73, 247251.
  • Von Auer, ch. , Oldenburg, J. , Von Depka, M. , Escuriola-Ettinghausen, C. , Kurnik, K. , Lenk, H. & Scharrer, I. (2005) Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates. Annals of NewYork Academy Sciecne, 1051, 498505.
  • Wight, J. & Paisley, S. (2003) The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia, 9, 418435.